A thousand milligrams of glutathione a day, taken for four weeks by forty healthy adults, moved nothing that the researchers could measure. The same daily dose, taken for six months by fifty-four adults, raised the body's stores by roughly a third. Both results come from randomized, placebo-controlled trials, both were published in peer-reviewed journals, and neither one is being misreported by the people who cite it.

The short answer for anyone standing in front of a shelf of oral glutathione supplements is that swallowing glutathione can raise glutathione, that it takes months rather than weeks, and that the effect leaves when the pills do. The longer answer involves what glutathione is actually made of, and why the research group with the most striking human results in this field spent its money on two cheaper amino acids instead.

Glutathione is assembled inside cells from glutamate, cysteine and glycine, and the cell builds it continuously rather than storing a reserve. Cysteine is the amino acid in shortest supply, which is why N-acetylcysteine occupies so much space in this conversation. A 2026 review in Frontiers in Nutrition put the mechanism plainly, noting that cysteine, provided by NAC, "is widely recognized as the rate-limiting precursor for GSH synthesis," while "advanced aging also precipitates a secondary bottleneck via systemic glycine deficiency." Two ingredients run short, and they run short at different points in a life.

What the oral glutathione trials actually measured

The favorable trial is the one most often cited on product pages. John Richie and colleagues at Penn State ran fifty-four non-smoking adults through six months of supplementation at either 250 or 1,000 milligrams daily, published the results in the European Journal of Nutrition, and found increases of roughly 30 to 35 percent in erythrocytes, plasma and lymphocytes at the higher dose. Buccal cells rose by 260 percent. Natural killer cell cytotoxicity more than doubled against placebo at the three month mark.

That same paper carries a sentence that rarely makes it into marketing copy, reporting that increases were dose dependent and time dependent and that "levels returned to baseline after a 1-month washout period." Richie, who has studied the molecule for more than thirty years, told Penn State's news office that "we believe glutathione supplementation may represent an effective intervention strategy for disease prevention and may enhance immune function." The claim is real and the reversal is real, and a shopper deserves both halves.

Jason Allen and Ryan Bradley gave forty adults 500 milligrams of glutathione twice daily for four weeks in a double-blind, placebo-controlled design, and found no significant change in erythrocyte glutathione, no movement in the oxidized-to-reduced ratio, and no separation on either oxidative stress marker, with F2-isoprostanes landing at p equals 0.38 and 8-OHdG at p equals 0.27. The daily dose matched Richie's high-dose arm exactly. The duration was one seventh as long.

Why the mechanism is still contested

Richie's trial drew a published objection arguing that glutathione must be broken down before it reaches cells, and Richie and his co-author replied in the same journal that they disagree, pointing to identified glutathione transporters in mammalian cells and to reports of direct absorption. They also conceded that the mechanisms remain under study. That exchange, between the authors of the most favorable trial in the field and their critics, is the most honest summary available of how settled this question is.

The trial that skipped glutathione entirely

Rajagopal Sekhar's group at Baylor College of Medicine took the other road. Their randomized trial, published in The Journals of Gerontology, enrolled twenty-four adults aged 61 to 80, randomized twelve to the combination of glycine and NAC and twelve to an alanine placebo, and ran for sixteen weeks at 100 milligrams per kilogram per day of each amino acid.

Red blood cell glutathione rose 225 percent. Two independent markers of oxidative stress, plasma TBARS and F2-isoprostane, each fell 72 percent. Gait speed improved 18 percent, from 1.13 to 1.34 meters per second. Grip strength in the dominant hand went from 32.3 to 36.7 kilograms at p equals 0.004, the chair-rise test fell from 25.6 seconds to 18.8 at p equals 0.002, and systolic blood pressure dropped from 132.0 to 124.4 millimeters of mercury at p equals 0.043. The placebo group showed no improvement on any of it. The six-minute walk finished at p equals 0.053, which is a trend and not a result, and the paper says so.

Sekhar, professor of medicine in endocrinology, diabetes and metabolism at Baylor, drew the distinction himself in the college's own research blog. "It is really important to understand that this trial supplemented GlyNAC, and did not supplement glutathione," he said. On the walking result he added that "gait speed is reported to be associated with survival in older humans," and that the finding "raises the interesting question of whether GlyNAC supplementation could have implications for survival in people."

In 2011 the same group gave eight adults aged 60 to 75 cysteine and glycine for fourteen days and watched red blood cell glutathione climb 94.6 percent while the fractional synthesis rate rose from 45.80 to 81.91 percent per day. Their conclusion, stated in the American Journal of Clinical Nutrition, was that glutathione deficiency in aging "is due in large part to decreased in vivo synthesis secondary to a decreased supply of the precursor amino acids glycine and cysteine." The cells had not stopped needing glutathione. They had run out of parts.

The dose nobody puts on a label

One hundred milligrams per kilogram per day works out to about seven grams of glycine and seven grams of NAC for a 70 kilogram adult. A typical retail NAC capsule holds 600 milligrams, so the Baylor regimen sits about a dozen capsules a day above what most cabinets contain, alongside a separate glycine dose that most glutathione supplement buyers are not taking at all.

The striking numbers belong to a research protocol in twenty-four older adults at a single center, not to a product, and no independent group has replicated them. The same Frontiers review that named cysteine as rate-limiting also reported that oral doses of 70 milligrams per kilogram raised plasma cysteine and glutathione "without major adverse effects, whereas 140 mg/kg caused significant gastrointestinal discomfort." The trial dose sits between those two figures, which is a reason to treat it as supervised research rather than a shopping list.

Where the FDA actually stands on NAC

The agency's final guidance of August 2022 states that "NAC is excluded from the dietary supplement definition" because it "was approved as a new drug before it was marketed as a dietary supplement or as a food." Rather than clearing shelves, the agency said it "intends to exercise enforcement discretion" for products that would otherwise be lawful, and noted that its initial review "has not revealed safety concerns with respect to the use of this ingredient in or as a dietary supplement." The ingredient sitting in half the cabinets in this category is legally a drug that regulators have chosen not to pursue while rulemaking continues.

A Japanese safety assessment of a nine gram dose, three times the amount used in the same group's earlier sleep work, concluded that "9 g of glycine produced neither acute serious adverse events nor a daytime sleepiness carry-over effect," with digestive symptoms appearing only when the dose was taken at bedtime.

What a shopper can do with this

A product promising to raise glutathione has one trial behind it at six months and one null trial at four weeks, and the honest expectation is a modest rise that fades within a month of stopping. A product promising the precursors has better mechanistic support and a small, unreplicated randomized trial at doses roughly ten times the capsules on the shelf.

Anyone already taking NAC and wondering why the effect feels thin is looking at a synthesis pathway that needs glycine alongside it, which is the specific insight the Baylor data contributes and the one most product labels skip. Anyone curious about what the cysteine donor does on its own can start with what N-acetylcysteine actually does, and anyone whose real complaint is fatigue rather than oxidative stress should read the mitochondrial evidence before buying either one.

The glutathione aisle rewards patience over dosage. Six months of a thousand milligrams produced a measurable change in fifty-four people, four weeks of the same amount produced none in forty, and a month off the pills returned the six-month group to where it started.